+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 1Day - 21Years
All Genders
ID03128996

Phase III Study of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplant in Children and Young Adults with Non-Malignant Disorders

Led by Washington University School of Medicine · Updated on 2026-05-29

29

Participants Needed

4

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of reduced intensity conditioning and familial HLA-mismatched bone marrow transplants in children and young adults under 21 years old with non-malignant disorders. These disorders include bone marrow failure syndromes, metabolic and immunologic disorders, hemoglobinopathies, and severe sickle cell disease. The study focuses on assessing donor cell engraftment and treatment toxicity in this population. Participants will receive a specific reduced intensity conditioning regimen that includes hydroxyurea, alemtuzumab, fludarabine, thiotepa, and melphalan over several weeks before undergoing a familial HLA-mismatched bone marrow transplant. After the transplant, they will receive a graft-versus-host disease GVHD prevention regimen with drugs such as cyclophosphamide, tacrolimus, mycophenolate mofetil, abatacept, and rituximab. Treatment and monitoring are planned for up to two years post-transplant. During the study, participants will be closely followed with regular assessments of donor engraftment at 100 days and one year after transplant. Researchers will also monitor neutrophil and platelet engraftment, pulmonary, hepatic, neurologic, cardiac, and renal function at multiple intervals. Pharmacokinetics of key drugs, incidence of acute and chronic GVHD, and immune system recovery will be evaluated. The total duration of participation and safety monitoring extends up to two years after the transplant.

CONDITIONS

Brief Title

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Research Team

S

Shalini Shenoy, MD

I

Ian Snyder, BS, CCRP

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here